Login to Your Account



ZymoGenetics Starts Pivotal rhThrombin Phase III Study

By Karen Pihl-Carey


Friday, October 28, 2005
Nearly three months after raising $135 million to move its lead blood-clotting agent into a pivotal study, ZymoGenetics Inc. started the Phase III trial of recombinant human Thrombin (rhThrombin) in surgery patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription